We are live on ! Find out more
FBRX icon

Forte Biosciences

59 hedge funds and large institutions have $315M invested in Forte Biosciences in 2025 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 21 increasing their positions, 7 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 6

200% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 7

103% more capital invested

Capital invested by funds: $155M → $315M (+$159M)

40% more funds holding

Funds holding: 4259 (+17)

8.79% more ownership

Funds ownership: 83.2%91.99% (+8.8%)

4% more call options, than puts

Call options by funds: $611K | Put options by funds: $589K

100% less funds holding in top 10

Funds holding in top 10: 20 (-2)

Holders
59
Holders Change
+17
Holders Change %
+40.48%
% of All Funds
0.72%
Holding in Top 10
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
New
24
Increased
21
Reduced
7
Closed
6
Calls
$611K
Puts
$589K
Net Calls
+$22K
Net Calls Change
+$23K
Name Holding Trade Value Shares
Change
Change in
Stake
Federated Hermes
1
Federated Hermes
Pennsylvania
$48.1M +$2.28M +130,136 +8%
FAM
2
Fred Alger Management
New York
$39.8M -$3.07M -175,059 -11%
Janus Henderson Group
3
Janus Henderson Group
United Kingdom
$39.2M +$385K +21,943 +2%
O
4
OrbiMed
New York
$32.6M
AAA
5
Affinity Asset Advisors
New York
$27M +$17.3M +989,490 New
Vanguard Group
6
Vanguard Group
Pennsylvania
$15.9M +$272K +15,522 +3%
Point72 Asset Management
7
Point72 Asset Management
Connecticut
$13.3M +$8.54M +487,275 New
CCC
8
Cable Car Capital
California
$10.9M -$1.75M -100,000 -20%
Adage Capital Partners
9
Adage Capital Partners
Massachusetts
$9.09M
WP
10
Woodline Partners
California
$9.05M
Fidelity Investments
11
Fidelity Investments
Massachusetts
$8.48M +$1.17M +66,565 +27%
IC
12
Ikarian Capital
Texas
$8.18M
Millennium Management
13
Millennium Management
New York
$6.73M +$2.22M +126,873 +106%
AIC
14
AWM Investment Company
New York
$6.46M -$438K -25,000 -10%
JG
15
Jain Global
New York
$5.52M +$3.55M +202,433 New
SFM
16
Sphera Funds Management
Israel
$5.07M -$5.06M -288,440 -61%
Ameriprise
17
Ameriprise
Minnesota
$4.17M +$1.46M +83,135 +119%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$3.4M +$286K +16,291 +15%
Morgan Stanley
19
Morgan Stanley
New York
$1.92M +$1.23M +70,380 +46,609%
Goldman Sachs
20
Goldman Sachs
New York
$1.85M +$1.19M +68,023 New
BlackRock
21
BlackRock
New York
$1.76M +$243K +13,834 +27%
JGC
22
J. Goldman & Co
New York
$1.66M +$1.07M +60,800 New
Susquehanna International Group
23
Susquehanna International Group
Pennsylvania
$1.44M +$928K +52,914 New
State Street
24
State Street
Massachusetts
$1.38M +$221K +12,624 +33%
6CM
25
683 Capital Management
New York
$1.09M +$701K +40,000 New

FBRX Hedge Fund Activity: Q4 2025 in Review

59 of the 8,245 institutional investors tracked by Wall St. Rank reported a position in Forte Biosciences (FBRX) for Q4 2025, worth a combined $315M — up 103% from $155M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new FBRX positions and 6 closed out — a net gain of 18 holders — while 21 added to existing stakes and 7 trimmed.

The largest buyer was Affinity Asset Advisors, opening a new position worth an estimated $17.3M. The largest seller was Sphera Funds Management, cutting an estimated $5.06M.

  • 59 institutional investors held Forte Biosciences (FBRX) as of Q4 2025, up from 42 in Q3 2025.
  • Funds reported $315M of Forte Biosciences stock for Q4 2025, up 103% quarter-over-quarter.
  • 24 funds opened new Forte Biosciences positions in Q4 2025 and 6 closed out, a net change of +18 holders.
  • The largest Forte Biosciences buyer in Q4 2025 was Affinity Asset Advisors, an estimated $17.3M added.
  • The largest Forte Biosciences seller in Q4 2025 was Sphera Funds Management, an estimated $5.06M sold.

Based on aggregated 13F filings for Q4 2025.